Patents by Inventor Paul E. G. Kristjansen
Paul E. G. Kristjansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210236634Abstract: The invention relates to combinational treatment using a monoclonal anti-alpha-synuclein antibody and an additional medicament. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy together with another medicament of the invention.Type: ApplicationFiled: December 1, 2020Publication date: August 5, 2021Applicant: H. Lundbeck A/SInventors: Pekka Kallunki, Paul E.G. Kristjansen
-
Patent number: 10889635Abstract: The invention relates to combinational treatment using a monoclonal anti-alpha-synuclein antibody and an additional medicament. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy together with another medicament of the invention.Type: GrantFiled: November 14, 2017Date of Patent: January 12, 2021Assignee: H. Lundbeck A/SInventors: Pekka Kallunki, Paul E. G. Kristjansen
-
Publication number: 20180194833Abstract: The invention relates to combinational treatment using a monoclonal anti-alpha-synuclein antibody and an additional medicament. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy together with another medicament of the invention.Type: ApplicationFiled: November 14, 2017Publication date: July 12, 2018Inventors: Pekka Kallunki, Paul E.G. Kristjansen
-
Patent number: 8785617Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analog, or Locked Nucleic Acid (LNA) or a combination thereof.Type: GrantFiled: December 21, 2012Date of Patent: July 22, 2014Assignee: Santaris Pharma A/SInventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E. G. Kristjansen
-
Patent number: 8357670Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: GrantFiled: May 22, 2012Date of Patent: January 22, 2013Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharama A/SInventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E. G. Kristjansen
-
Publication number: 20120270924Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: ApplicationFiled: May 22, 2012Publication date: October 25, 2012Applicants: Santaris Pharma A/S, Enzon Pharmaceuticals. Inc.Inventors: Charlotte Albæk Thrue, Anja Mølhart Høg, Paul E.G. Kristjansen
-
Patent number: 8207140Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: GrantFiled: October 27, 2010Date of Patent: June 26, 2012Assignees: Santaris Pharma A/S, Enzon Pharmaceuticals, Inc.Inventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E. G. Kristjansen
-
Publication number: 20110224285Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: ApplicationFiled: October 27, 2010Publication date: September 15, 2011Applicants: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventors: Charlotte Albaek Thrue, Anja Molhart Høg, Paul E.G. Kristjansen
-
Patent number: 7846911Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIP-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: GrantFiled: October 15, 2009Date of Patent: December 7, 2010Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E. G. Kristjansen
-
Patent number: 7737264Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: GrantFiled: April 4, 2003Date of Patent: June 15, 2010Assignees: Santaris Pharma A/SInventors: Charlotte Albæk Thrue, Anja Mølhart Høg, Paul E. G. Kristjansen
-
Publication number: 20100093839Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIP-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: ApplicationFiled: October 15, 2009Publication date: April 15, 2010Applicants: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E.G. Kristjansen
-
Publication number: 20040096848Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1&agr; (HIF-1&agr;) gene are provided for modulating the expression of HIF-1&agr;. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1&agr;. Methods of using these compounds for modulation of HIF-1&agr; expression and for the treatment of diseases associated with the hypoxia-inducible factor-1&agr; are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: ApplicationFiled: October 23, 2003Publication date: May 20, 2004Inventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E.G. Kristjansen
-
Patent number: 6701171Abstract: The present invention relates to a method for non-invasive local quantification of angiogenesis or destruction of existing blood vessels in living tissue, the use of the said method for local measurements of hemoglobin concentration and blood perfusion at the same location on the subject and an apparatus for carrying out the method according to the invention. The apparatus comprises a xenon flash unit, an optical filter and a Y-shaped optical fiber-bundle, one branch of the fiber-bundle being coupled to the flash unit and the other branch of the fiber-bundle being coupled to a detection unit and the merged part of the fiber-bundle being adapted to couple the apparatus to the tissue to be tested.Type: GrantFiled: February 8, 2001Date of Patent: March 2, 2004Assignee: Københavns UniversitetInventors: Bjørn Quistorff, Paul E. G. Kristjansen, Michael Kragh